Document Detail

The effect of lipid and inflammatory profiles on the morphological changes of lipid-rich plaques in patients with non-ST-segment elevated acute coronary syndrome: follow-up study by optical coherence tomography and intravascular ultrasound.
MedLine Citation:
PMID:  20650439     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: The aim of this study was to determine the relationship between the morphological changes of nonculprit lipid-rich plaques and several clinical profiles in patients with non-ST-segment elevated acute coronary syndrome (NSTEACS).
BACKGROUND: Identification of coronary lesion with morphological characteristics of rupture-prone plaques is still difficult.
METHODS: Eighty-two consecutive patients with NSTEACS who underwent percutaneous coronary intervention were enrolled. The changes in total atheroma volume (TAV) of residual nonculprit lipid-rich plaques and the changes in the corresponding fibrous cap thickness (FCT) were assessed by intravascular ultrasound and optical coherence tomography, respectively, at baseline and after 9 months.
RESULTS: The percentage changes in TAV (mm(3)) of lipid-rich plaques and in the corresponding FCT (microm) over the 9-month follow-up period were 3.1 +/- 11% and 15 +/- 17%, respectively. There was no significant correlation between the changes in TAV and those in FCT. The change in TAV showed a significant correlation with reduction of the low-density lipoprotein/high-density lipoprotein (LDL/HDL) ratio (r = 0.42, p < 0.01). In contrast, the change in FCT showed no correlation with LDL/HDL ratio but had a significant positive correlation with changes in high-sensitivity C-reactive protein (r = 0.44, p < 0.01). Furthermore, in multivariate logistic analysis, statin use was an independent predictor of changes in well-stabilized plaques that showed both TAV reduction and FCT increase.
CONCLUSIONS: The changes in TAV and FCT of coronary plaques over a 9-month observation period were related to 2 different independent factors (i.e., reduction of LDL-cholesterol and high-sensitivity C-reactive protein, respectively). Furthermore, lipid-lowering therapy with statin has the potential to stabilize these parameters by both plaque reduction and FCT.
Shigeho Takarada; Toshio Imanishi; Kohei Ishibashi; Takashi Tanimoto; Kenichi Komukai; Yasushi Ino; Hironori Kitabata; Takashi Kubo; Atsushi Tanaka; Keizo Kimura; Masato Mizukoshi; Takashi Akasaka
Related Documents :
10712399 - Cholesterol-lowering treatment is associated with improvement in coronary vascular remo...
16036039 - Do statins prevent heart failure in patients after myocardial infarction?
15330739 - Atorvastatin versus pravastatin: intensive versus moderate lipid lowering.
9242969 - Clinical characteristics of double heterozygotes with familial hypercholesterolemia and...
12532169 - Statins in acute coronary syndromes.
19514639 - Serum levels of interleukin-6, interleukin-10 and c-reactive protein in patients with m...
15562839 - Catheter-based transendocardial delivery of autologous bone-marrow-derived mononuclear ...
20946319 - Diannexin reduces no-reflow after reperfusion in rabbits with large ischemic myocardial...
15877999 - Effect of nifedipine on c-reactive protein levels in the coronary sinus and on coronary...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  JACC. Cardiovascular interventions     Volume:  3     ISSN:  1876-7605     ISO Abbreviation:  JACC Cardiovasc Interv     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-07-23     Completed Date:  2010-11-08     Revised Date:  2014-09-05    
Medline Journal Info:
Nlm Unique ID:  101467004     Medline TA:  JACC Cardiovasc Interv     Country:  United States    
Other Details:
Languages:  eng     Pagination:  766-72     Citation Subset:  IM    
Copyright Information:
Copyright 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Coronary Syndrome / blood,  diagnosis,  etiology,  therapy*
Aged, 80 and over
Angioplasty, Balloon, Coronary*
Biological Markers / blood
C-Reactive Protein / metabolism*
Cholesterol, HDL / blood
Cholesterol, LDL / blood*
Coronary Angiography
Coronary Artery Disease / blood,  complications,  diagnosis,  therapy*
Coronary Vessels* / pathology,  ultrasonography
Cross-Sectional Studies
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Inflammation Mediators / blood*
Logistic Models
Middle Aged
Odds Ratio
Risk Assessment
Risk Factors
Time Factors
Tomography, Optical Coherence*
Treatment Outcome
Ultrasonography, Interventional*
Reg. No./Substance:
0/Biological Markers; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Inflammation Mediators; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Transcatheter closure of paravalvular defects using a purpose-specific occluder.
Next Document:  Insurance type influences the use of drug-eluting stents.